A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

• Status: Unknown status
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD. First-degree relatives of PD will be recruited through PD research sites and national foundations to participate in this study. In addition, first degree relatives of PD patients will be recruited directly through advertising.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Institute for Neurodegenerative Disorders
• Collaborators: Molecular NeuroImaging; United States Department of Defense

Criteria

At Risk - Inclusion Criteria:

• subject must have a first-degree relative with PD, based on their report

• subject must not carry a diagnosis of PD or other neurodegenerative disorder.

• subject must be either at least 50 yrs old or within 10 yrs of the age of onset of their affected relative

• Subject must have no other known reason for abnormal olfaction (e.g. nasal trauma, sinus infection, sinus surgery)

• Subject must not be pregnant if participating in the imaging portion of this study

Non-First Degree Relative - Inclusion Criteria:

• Subject must not carry a diagnosis of PD or other neurodegenerative disorders

• Subject must have no other known reason for abnormal olfaction (e.g. nasal trauma, sinus infection, sinus surgery)

• Subject must not be pregnant or be an actively nursing mother if participating in the imaging portion of this study.

Exclusion Criteria:

• diagnosis of PD or other neurodegenerative disorder

• other known reason for abnormal olfaction (e.g. nasal trauma, sinus infection, sinus surgery)

• pregnancy, if participating in the imaging portion of this study